25. The power of AI for precision drug discovery and development: Auransa Inc., Andy Protter, CSO

25. The power of AI for precision drug discovery and development: Auransa Inc., Andy Protter, CSO

Andy Protter, PhD. joined Auransa in January 2017 as Chief Scientific Officer with 35 years of pharmaceutical industry research and development experience. At Auransa, Dr. Protter has led preclinical R&D which uses AI technology to discover novel drug candidates. Auransa’s lead project for hepatocellular carcinoma has completed all IND-supporting preclinical safety studies. Prior to joining Auransa, Dr. Protter was a Vice President at Medivation where he was responsible for preclinical pharmacology and toxicology of Enzalutamide, a prostate cancer drug that was approved by the FDA. Prior to Medivation, Dr. Protter worked at Scios, a biotechnology company where he also lead preclinical development. Dr. Protter initiated the Natrecor development program and was responsible for all preclinical activities. Natrecor was approved by the FDA for acute decompensated congestive heart failure. In addition Dr. Protter led preclinical efforts selecting a p38 MAP kinase inhibitor drug candidate that was tested in patients with rheumatoid arthritis and surgical pain. In 2004 Johnson and Johnson awarded Dr. Protter the Johnson Medal for his work on Natrecor. Trained as a biochemist at the State University of New York at Stony Brook, Dr. Protter led the first successful cloning of apolipoprotein B, the primary protein on LDL. He has participated in work described in over 84 published papers, 4 book chapters and 28 patents. When not doing science, Andy enjoys hobbies including biking, skiing, sailing, photography and reading.

Tämä jakso on lisätty Podme-palveluun avoimen RSS-syötteen kautta eikä se ole Podmen omaa tuotantoa. Siksi jakso saattaa sisältää mainontaa.

Jaksot(265)

Robert Plenge, EVP & Chief Research Officer, BMS: Reinventing Drug Discovery

Robert Plenge, EVP & Chief Research Officer, BMS: Reinventing Drug Discovery

Synopsis: The drug discovery industry faces a persistent challenge: 9 out of 10 drugs entering the clinic fail, underscoring the need for a better path from biological insight to transformative medi...

24 Syys 45min

Nello Mainolfi, Founder, President & CEO, Kymera: Pioneering Targeted Protein Degradation

Nello Mainolfi, Founder, President & CEO, Kymera: Pioneering Targeted Protein Degradation

Synopsis: What does it take to turn a once-fringe scientific idea into a new approach to drug discovery—and build a biotech company around it for the long haul? In this episode of Biotech 2050, hos...

16 Syys 38min

Nick Myerberg, Partner & Head of AI at Braidwell on AI's Next Era in Drug Discovery

Nick Myerberg, Partner & Head of AI at Braidwell on AI's Next Era in Drug Discovery

Synopsis: The guest on today's podcast is a representative of Braidwell LP, a registered investment adviser. Braidwell invests on behalf of its clients and either holds, or may in the future hold, p...

3 Elo 47min

Robert Jacks, CEO of Sparrow Pharmaceuticals | Precision Medicine, Biotech Strategy & Leadership

Robert Jacks, CEO of Sparrow Pharmaceuticals | Precision Medicine, Biotech Strategy & Leadership

Synopsis: In an industry often defined by rapid innovation and high-stakes science, long-term success in biotech requires more than breakthrough discoveries—it demands strategic clarity, resilient l...

22 Heinä 34min

Ardelyx Leaders Mike Raab & Laura Williams on Building Biotech Around Patients

Ardelyx Leaders Mike Raab & Laura Williams on Building Biotech Around Patients

Synopsis: While biotech is increasingly measured by clinical milestones and financial outcomes, Rahul Chaturvedi welcomes two leaders who argue that true success begins and ends with patients. In th...

10 Kesä 41min

Acadia CEO Catherine Owen Adams on Neurodegeneration, AI & Building Biotech Vision

Acadia CEO Catherine Owen Adams on Neurodegeneration, AI & Building Biotech Vision

Synopsis: At the intersection of personal mission and biotech leadership, Rahul Chaturvedi sits down with Catherine Owen Adams, CEO of Acadia Pharmaceuticals, for a deeply personal and strategically...

13 Touko 33min

Barry Quart, CEO of Connect Biopharma, on Asthma Innovation & Biotech Leadership

Barry Quart, CEO of Connect Biopharma, on Asthma Innovation & Biotech Leadership

Synopsis: This episode is proudly sponsored by Quartzy. At a time when biotech innovation is being reshaped by science, capital, and global dynamics, Alok Tayi sits down with Barry Quart, CEO of Co...

16 Huhti 23min

Adial CEO Cary Claiborne on Treating Alcohol Addiction with Genetics

Adial CEO Cary Claiborne on Treating Alcohol Addiction with Genetics

Synopsis: Addiction is often misunderstood as a failure of willpower—but emerging science increasingly shows it may be deeply rooted in biology. In this episode of Biotech 2050, recorded during JPM...

6 Maalis 14min

Suosittua kategoriassa Tiede

rss-mita-tulisi-tietaa
rss-poliisin-mieli
utelias-mieli
rss-hereilla
tiedekulma-podcast
rss-duodecim-lehti
rss-luontopodi-samuel-glassar-tutkii-luonnon-ihmeita
hippokrateen-vastaanotolla
rss-bios-podcast
docemilia
rss-politiikasta-podcast
rss-tiedetta-vai-tarinaa
rss-ranskaa-raakana
rss-lihavuudesta-podcast
radio-antro
rss-radplus